Abstract No. 616 Lusutrombopag is a safe treatment option for thrombocytopenia in patients with chronic liver disease undergoing a planned invasive procedure: pooled safety analysis from three studies

Lusutrombopag (LUSU) is a thrombopoietin receptor agonist (TPO-RA) approved in Japan and US for treatment of thrombocytopenia (TCP), and in EU for severe TCP, associated with chronic liver disease (CLD) in patients undergoing planned invasive procedures (IP). TPO-RAs have been associated with increased risk of thrombotic events in patients with CLD and a safety assessment of new agents is critical. LUSU safety was assessed in a pooled retrospective analysis of three clinical studies.
Source: Journal of Vascular and Interventional Radiology : JVIR - Category: Radiology Authors: Tags: Scientific e-Poster Source Type: research